MX2022007947A - Derivado de amida de acido alifatico. - Google Patents

Derivado de amida de acido alifatico.

Info

Publication number
MX2022007947A
MX2022007947A MX2022007947A MX2022007947A MX2022007947A MX 2022007947 A MX2022007947 A MX 2022007947A MX 2022007947 A MX2022007947 A MX 2022007947A MX 2022007947 A MX2022007947 A MX 2022007947A MX 2022007947 A MX2022007947 A MX 2022007947A
Authority
MX
Mexico
Prior art keywords
sup
sub
acid amide
aliphatic acid
amide derivative
Prior art date
Application number
MX2022007947A
Other languages
English (en)
Inventor
Andrew Simon Bell
Yoshinori Aihara
Jeremy Besnard
Yuki Fujii
Masayuki Sakuma
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of MX2022007947A publication Critical patent/MX2022007947A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Abstract

La presente invención se refiere a un compuesto representado por la fórmula (1) (ver Fórmula), teniendo el compuesto actividad antagonista contra los receptores de serotonina 5-HT2A y los receptores de serotonina 5-HT7; o una sal farmacéuticamente aceptable del compuesto; (en la fórmula, Z es un átomo de nitrógeno y similares; Y es carbonilo y similares; m y n son 1 y similares; R1a a R1d, R2a a R2d, y R4a a R4d son átomo de hidrógeno y similares; R3 es alquilo y similares; y Q es un grupo bicíclico específico).
MX2022007947A 2019-12-24 2020-12-23 Derivado de amida de acido alifatico. MX2022007947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019232927 2019-12-24
PCT/JP2020/048117 WO2021132311A1 (ja) 2019-12-24 2020-12-23 脂肪族酸アミド誘導体

Publications (1)

Publication Number Publication Date
MX2022007947A true MX2022007947A (es) 2022-07-27

Family

ID=76574184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007947A MX2022007947A (es) 2019-12-24 2020-12-23 Derivado de amida de acido alifatico.

Country Status (11)

Country Link
US (2) US20220213079A1 (es)
EP (1) EP4082616A4 (es)
JP (1) JPWO2021132311A1 (es)
KR (1) KR20220120625A (es)
CN (1) CN114981264A (es)
AU (1) AU2020413284A1 (es)
BR (1) BR112022011844A2 (es)
CA (1) CA3161806A1 (es)
MX (1) MX2022007947A (es)
TW (1) TW202136235A (es)
WO (1) WO2021132311A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880930A (en) * 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
EP0732332B1 (en) * 1995-03-17 2001-12-19 Aventis Pharmaceuticals Inc. Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
US5880121A (en) * 1996-01-05 1999-03-09 Hoechst Marion Roussel Inc. 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof
JP4497815B2 (ja) * 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンd3受容体リガンドとしてのその使用
FR2827287B1 (fr) * 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR0316108A (pt) * 2002-11-08 2005-09-27 Warner Lambert Co Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos
ATE461925T1 (de) 2005-04-26 2010-04-15 Hypnion Inc Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung
PL392436A1 (pl) * 2010-09-17 2012-03-26 Adamed Spółka Z Ograniczoną Odpowiedzialnością Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
WO2014079155A1 (zh) * 2012-11-26 2014-05-30 辽宁贝雷生物制药有限公司 苯并五元氮杂环基哌嗪或哌啶衍生物的用途

Also Published As

Publication number Publication date
WO2021132311A1 (ja) 2021-07-01
US11339151B2 (en) 2022-05-24
KR20220120625A (ko) 2022-08-30
JPWO2021132311A1 (es) 2021-07-01
US20220213079A1 (en) 2022-07-07
EP4082616A1 (en) 2022-11-02
US20220073506A1 (en) 2022-03-10
CA3161806A1 (en) 2021-07-01
AU2020413284A1 (en) 2022-08-18
CN114981264A (zh) 2022-08-30
EP4082616A4 (en) 2024-01-03
TW202136235A (zh) 2021-10-01
BR112022011844A2 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
IN2012CN09242A (es)
RU2012126129A (ru) Производное индола и его фармацевтическое применение
EA200701583A1 (ru) Гетероциклические тетрациклические производные гидрофурана в качестве ингибиторов 5нт2 в терапии расстройств цнс
EA200701640A1 (ru) Новые соединения с терапевтическим эффектом
EA200400981A1 (ru) Новые гетероциклические соединения, активные в качестве ингибиторов бета-лактамаз
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
MX2009004910A (es) Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo.
HK1071366A1 (en) Compounds which inhibit the release of inflammatory cytokines
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
MX2015008971A (es) Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor.
TW200745058A (en) MMP-13 selective inhibitors
UA108510C2 (en) Cyclopropane compound
MY193597A (en) Novel pyrrolidine compound and application as melanocortin receptor agonist
PH12017501655B1 (en) Morphinan derivative
EA200601178A1 (ru) Морфолинилсодержащие бензимидазолы в качестве ингибиторов репликации респираторно-синцитиального вируса
ZA202108263B (en) Imidazolonylquinoline compounds and therapeutic uses thereof
SG11201810725WA (en) Novel β-lactamase inhibitors
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2022007947A (es) Derivado de amida de acido alifatico.
IN2013MN00506A (es)
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
AU2003257433A8 (en) Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors
MX2023003245A (es) Derivados de amina novedosos.
MX2023006176A (es) Nuevos derivados de indazol acetileno.